Skip to main content

Table 1 Characteristics of the conversion therapy group and the palliative chemotherapy group

From: Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study

Variable conversion therapy (n = 18) palliative chemotherapy (n = 20) p-Value
Gender    0.321
 Male 7 11
 Female 11 9
Median age 49.8(28 ~ 72) 53.5(35 ~ 73) 0.185
Tumor location
 Upper 1 4  
 Middle 11 10  
 Lower 6 6 0.417
Differentiation    0.758
 Well and moderately 9 11
 Poorly 9 9
Initial DSL    0.321
 PCI < 10 11 9
 PCI ≥ 10 7 11
Second DSL    <0.001
 PCI < 6 18 2
 PCI ≥ 6 0 18
Ascites    0.516
 Positive 8 11
 Negative 10 9
Serum CEA (ng/ml)    0.544
 Normal 15 18
 >5 3 2
Serum CA19–9 (U/ml)    0.914
 Normal 12 13
 >39 6 7
Serum CA125 (U/ml)    0.703
 Normal 7 9
 >35 11 11
Serum CA724 (U/ml)
 Normal 12 15 0.532
 >7 6 5
  1. DSL diagnostic staging laparoscopy, PCI peritoneal carcinomatosis index
  2. CEA carcinoembryonic antigen
\